Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.
Summary
The Executive Director, Commercial Strategy & Execution will lead strategic portfolio or country-level initiatives, drive launch readiness preparation for key markets, help develop and implement strategic and executional plans, optimize sales and marketing operations, and build / adopt commercial capabilities within key markets.
Your Role:
- Lead and manage key portfolio or country-level initiatives for the CCO in collaboration with key Commercial functions related to key business priorities
- Partner closely with cross-functional groups (e.g., Insights & Analytics, R&D, Market Access, Marketing / Sales, Regulatory Affairs, Finance, and Medical Affairs) for the development and implementation of strategic and executional plans
- Continually monitor and analyze market, customer, and competitor trends, incorporating insights into commercial plans
- Build launch excellence capabilities to ensure successful, coordinated and cross-functional launch preparations
- Drive development of launch plans and tracking tools to advance portfolio commercialization efforts
- Partner closely with all cross-functional groups and stakeholders across the company that are involved in Launch Readiness (e.g., Commercial teams, Supply Chain, Manufacturing, Finance, Regulatory Affairs, HR to drive launch preparation and ensure effective communication across the internal teams
- Support Alliance Management team with leading and optimizing strategic collaborations by providing appropriate Commercial perspectives and direction to maximize value of global partnerships
- Oversee critical initiatives to drive excellence in culture, operations and ways of working
What You Bring:
- Bachelor's degree required
- Life sciences, biotech, or pharma company professional with 15+ years of experience or equivalent work experience
- Prior working experience within a pharma Commercial team and within Oncology
- Strong working knowledge of legal landscape, FDA promotional regulations, standard operating procedures, and biotech development process required.
- Excellent organizational, analytical, and communication skills
- Ability to manage projects and changing priorities, multitask, and meet aggressive deadlines in a fast-paced environment.
- Resourceful and driven, enthusiastic to collaborate with cross-functional teams and departments.
- Ability to thrive in a dynamic and evolving environment, with a proactive and adaptable mindset to navigate change and drive continuous improvement
#LI-Hybrid
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Skills Required
- Bachelor's degree
- 15+ years of experience in a life sciences, biotech, or pharmaceutical company, or equivalent experience
- Prior experience within a pharmaceutical commercial team
- Prior experience in oncology
- Strong working knowledge of the legal landscape
- Knowledge of FDA promotional regulations
- Knowledge of standard operating procedures
- Knowledge of the biotech development process
- Strong organizational, analytical, and communication skills
- Ability to manage projects, changing priorities, multiple tasks, and aggressive deadlines
- Ability to collaborate effectively with cross-functional teams
- Proactive, adaptable, and continuous-improvement mindset
What We Do
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
